Medical University of Warsaw and Instytut Farmaceutyczny | Date: 2017-02-01
The present invention relates to the antipsoriatic emulsion composition, especially in the form of a cream, comprising an effective therapeutic dose of cefazolin, the ingredients of the oil phase and the ingredients of the water phase, characterized by that(i) the ingredients of the oil phase include:- liquid paraffin or white petrolatum,- polyoxyethylene stearyl ether (21), and- cetostearyl alcohol;(ii) the ingredients of the oil phase include a buffer solution to maintain the pH value of the initial composition from 5 to 9, preferably in the range 6 - 8,(iii) optionally, comprising an additional amphiphilic nonionic emulsifier, and other soluble/water miscible excipients,wherein water content accounts for 50 to 80% by weight of the composition.
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2012-ITN | Award Amount: 3.31M | Year: 2013
Our ITN has both scientific and therapeutic targets. Research in Work Package 1 (WP1) aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). Research in WP2 will use the information gained from WP1 to develop ways of alleviating the differentiation block in AML and so deliver new agents for use in differentiation therapy. This type of therapy aims, using only mildly toxic treatments, to induce terminal maturation of leukaemia cells and accelerate their death. WP2 responds to the urgent need to devise milder treatments, especially for older and frailer AML patients. Participants have already identified a number of promising new therapeutic agents. Working across these two complementary areas will train our Early Stage Researchers (ESR) to understand the translation of new fundamental science into the development of new therapies. The ITN brings together scientists who have made important advances in the fields of haematopoiesis and differentiation therapy, so will provide an excellent scientific training in these areas. Secondments/visits by ESRs to participants who run centres of expertise in leading edge technologies will provide training in these; and the time spent with private sector participants, and the courses they provide, will ensure that ESRs acquire the transferable skills they will need if they are to work well in, and build bridges between, commercial and publicly funded research organisations. ESRs will also receive management training. This research and training, which will develop our ESRs as versatile scientists, will involve the combined efforts of prestigious research institutes and universities, Polands leading governmental pharmaceutical R & D institute, two successful biopharmaceutical companies and a leading management consultancy.
Medical University of Warsaw and Instytut Farmaceutyczny | Date: 2013-01-03
A process for the preparation of protoescigenin by hydrolysis of escin isolated from Aesculus hippocastanum. The process includes the following steps: a two-step hydrolysis first under acidic and then basic conditions, enrichment of the crude mixture of sapogenins with protoescigenin, an isolation of the mixture of sapogenins in a solid form, and a purification of the obtained solid and isolation of high purity protoescigenin. The invention also relates to protoescigenin monohydrate in a crystalline form and the preparation thereof. Protoescigenin is a polyhydroxy aglycone, which can be used as a synthon in the chemical modifications of naturally occurring saponins.
Medical University of Warsaw and Instytut Farmaceutyczny | Date: 2016-08-31
The present invention relates to a protoescigenin derivative having pharmacological properties, process of its preparation, use of such compound as medicament especially for treating vascular disorders, as well as to a pharmaceutical composition comprising such compound.
Medical University of Warsaw and Instytut Farmaceutyczny | Date: 2015-11-04
A non-human animal mammalian model for Parkes-Weber syndrome, wherein an animal has an arteriovenous fistula and a venous ligature in at least one of the limbs, is provided. The invention also relates to a method for preparing the model. The desired model reflects the pathophysiological characteristics of PW syndrome and can be used in studies on PW syndrome, including etiology of the syndrome. The animal model can also be used for screening a material for vascular use and for screening a preventive and/or therapeutic agent for Parkes-Weber syndrome.
Medical University of Warsaw, Instytut Farmaceutyczny and Instytut Biochemii I Biofizyki Polskiej Akademii Nauk | Date: 2016-10-12
The subject invention relates to agents for use in treatment and/or prevention of Alzheimers disease. The group of agents include horse chestnut extract, escins, their salts and derivatives.
Instytut Farmaceutyczny | Date: 2012-03-29
A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatmenta therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis.
Instytut Farmaceutyczny | Date: 2010-01-11
A process for the preparation of calcipotriol at least including: (a) reacting a C-22 phenylsulfonyl derivative of cholecalciferol of Formula 2, wherein R_(1 )and R_(2 )are the same or different and represent hydroxyl protecting groups, with a silyl derivative of alfa-hydroxy aldehyde of Formula 3, wherein R_(3 )represents silyl group of formula Si(R_(4))(R_(5))(R_(6)), where R_(4)-R_(6 )are the same or different and represent C_(1-6 )alkyl or phenyl groups, in the presence of a strong organic base in an aprotic solvent, followed by reductive desulfonation of the obtained diastereomeric mixture of alfa-hydroxysulfones with sodium amalgam, removal of the hydroxyl protecting groups, and purification of the product. The process leads to the formation of calcipotriol containing less than 0.3% of the (22Z)-isomer. The obtained calcipotriol is free of mercury traces.
Instytut Farmaceutyczny | Date: 2013-12-16
A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis. A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatmenta therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof.
Instytut Farmaceutyczny | Date: 2013-03-08
A convergent synthesis of the prostaglandin F_(2) analogues, travoprost and bimatoprost, was developed employing Julia-Lythgoe olefination of the structurally advanced phenylsulfone with an enantiomerically pure aldehyde -chain synthon. The novel convergent strategy allows the synthesis of a whole series of prostaglandin analogues of high purity from a common and structurally advanced prostaglandin intermediate.